Objective:

To identify lipid signals linked to retinal degeneration and assess the effects of restoring erucamide levels.

Approach:

• Metabolomics Screening: Researchers conducted an unbiased high-resolution metabolomics screen in rodent models of retinal degeneration to identify candidate signals.
• Lipid Delivery: Erucamide was packaged into organosilane-modified porous silicon nanoparticles for delivery into the eye.
• Mechanistic Studies: Confocal imaging and gene-expression analysis were used to investigate the uptake of erucamide by retinal myeloid cells and its signaling mechanisms.

Key Findings:

• Erucamide levels decrease as photoreceptors deteriorate in retinal degeneration models, including RCS rats and rd10 mice.
• Restoring erucamide improves neurovascular outcomes, preserving retinal layer thickness and improving scotopic ERG responses.
• Erucamide is taken up by CD11b+ retinal myeloid cells, which are linked to vascular and neuronal support.
• TMEM19 was identified as a candidate erucamide-binding protein, with its knockdown weakening the signaling response and retinal benefits.

Interpretation:

Erucamide may coordinate the retinal response to injury by engaging the surrounding environment rather than directly targeting photoreceptors.

Limitations:

• The study primarily focused on rodent models, necessitating further testing in additional retinal disease models.

Conclusion:

The findings suggest a potential new pathway for treating degenerative retinal diseases by modulating existing lipid signals, warranting further testing in additional retinal disease models.